SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune ...

CytomX expects to use the net proceeds from this offering for the continued development of Varseta-M and other pipeline programs. CytomX expects to use any remaining net proceeds from this offering ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

A 2026 company-issued informational report covering NatureGlyco's product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching ...

A 2026 consumer warning report examining DentaBiome's oral postbiotic formula, how FabM acid-lock and 30-second kitchen method claims relate to published research, the ingredient research context ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The ...

SugarHarmony Research has released ingredient reference materials outlining the compounds associated with Blood Sugar Harmony Liquid Drops, citing scientific references and ingredient context as part ...

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the ...

About TNX-1700 TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed ...

Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine ...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting ...